A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China (ADAPT)

AbbVie

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT03236870

P15-986

Details and patient eligibility

About

The objective of this non-interventional, observational study is to assess the effectiveness and patient reported outcome of adalimumab in patients with moderate to severe psoriasis in real world clinical practice in China.

Enrollment: 181 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant who is in compliance with eligibility for adalimumab based on the local label;
• Moderate to severe plaque psoriasis patients eligible to use adalimumab according to the local label without any contraindication
• Patients have signed the authorization (or informed consent where applicable) to disclose and use personal health information after been prescribed with adalimumab.

Exclusion criteria

• Patients who are pregnant or breast feeding at enrolment or wish to become pregnant during the following adalimumab treatment and within 150 days since adalimumab discontinuation;
• Patients in any psoriasis related clinical trial at the time of enrolment, at baseline or at any point during the study follow-up;
• Patients with active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) as well as moderate to severe cardiac insufficiency.
• Patients with difficulties for adequately reading, understanding and completing patient questionnaires.

Trial design

181 participants in 1 patient group

Participants with moderate to severe plaque psoriasis in China

Description:

Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.